VANCOUVER, BC, March 3, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Firm”), a pacesetter within the growth of psilocybin and different entheogens, is happy to announce the launch of its US-based Observational Examine NM-101: “Microbiotic Variety in Autism Spectrum Dysfunction (ASD): Enhancing Diagnostics by Differentiating Subtypes.”
“NOVA’s mission is to find extra exact methods to diagnose and deal with autism spectrum dysfunction (ASD), an unmet medical want,” said Julia V. Perederiy, PhD, NOVA’s Lead Scientist and Principal Investigator on the research.
“This scientific investigation is a vital first step in precisely defining subsets or cohorts of ASD sufferers that may greatest reply to particular psilocybin and entheogen remedy. Microbiome science and investigation continues to achieve deeper insights into intestine biology and its affect over mind exercise and behavior,” she continued.
This research will assess the intestine microbiome throughout varied subtypes of ASD (together with fragile X syndrome) through genetic evaluation of fecal samples, evaluating bacterial profiles with these from age-matched neurotypical controls. This analysis is critical as a result of shifts in intestine micro organism contribute to the pathophysiology of GI issues1, that are 4 instances extra frequent amongst kids with ASD2 and are related to worsening of behavioural signs, together with anxiousness, hypersensitivity and rigid-compulsive behaviours3.
NOVA’s observational scientific research goals to recruit a minimum of 300 members throughout the U.S.: 200+ with reasonable/extreme ASD and 100+ neurotypical controls. The big-scale design of this research, in addition to inclusion of multidimensional datasets and proprietary machine studying programs, goals to resolve inconsistencies in prior scientific research relating to the function of intestine microbiota in ASD, significantly with regard to diagnostics and therapy – at the moment an unmet medical want.
“A research of this dimension will enable us to make use of machine studying to section the affected person inhabitants into teams primarily based on microbiome traits, genomics and efficiency on behavioural checks,” mentioned Kyle H. Ambert, PhD, of NOVA’s Scientific Advisory Board. “Our findings right here will assist enhance ASD diagnostic strategies, permitting us to quantify illness severity utilizing one thing apart from behavioural strategies alone.”
Examine information will enable NOVA to develop an ASD Diagnostic Index and help the corporate within the design and implementation of a deliberate Part I Medical Trial for NOVA’s lead psychedelic compound (PILZ 1013). Furthermore, this research will likely be utilized in preliminary conversations with the U.S. FDA to outline the optimum regulatory pathway and speed up NOVA’s drug growth program.
- Vich Vila A, Imhann F, Collij V, et al. (December 2018). “Intestine microbiota composition and practical modifications in inflammatory bowel illness and irritable bowel syndrome.” Sci Transl Med. 10(472):eaap8914.
- McElhanon BO, McCracken C, Karpen S, Sharp WG (Could 2013). “Gastrointestinal signs in autism spectrum dysfunction: a meta-analysis.” Pediatrics. 133(5):872-83.
- Mazurek MO, Vasa RA, Kalb LG, Kanne SM, et al. (January 2013). “Anxiousness, sensory over-responsivity, and gastrointestinal issues in kids with autism spectrum issues.” J Abnorm Baby Psychol. 41(1):165-76.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology firm that’s centered on the rising subject of serotonergic psychedelic medication, comparable to psilocybin and its associated tryptamine derivatives. The Firm is a worldwide chief on this subject by integrating the newest state-of-the-art medical and scientific expertise into its drug growth program. The purpose is to diagnose and deal with debilitating persistent situations which have unmet medical wants, comparable to autism spectrum dysfunction (ASD).
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Neither the Canadian Securities Change nor its Market Regulator (as that time period is outlined within the insurance policies of the Canadian Securities Change) accepts duty for the adequacy or accuracy of this launch.
This information launch incorporates statements that represent “forward-looking statements.” Such ahead trying statements contain identified and unknown dangers, uncertainties and different elements which will trigger Nova Mentis Life Science’s precise outcomes, efficiency or achievements, or developments within the trade to vary materially from the anticipated outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Ahead trying statements are statements that aren’t historic details and are typically, however not all the time, recognized by the phrases “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “initiatives,” “potential” and related expressions, or that occasions or situations “will,” “would,” “might,” “may” or “ought to” happen.
SOURCE Nova Mentis Life Science Corp.
For additional info: Cellphone: 778-819-0244, Toll Free: 1-833-542-5323